Anika Therapeutics (ANIK) vs BioAge Labs (BIOA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Anika Therapeutics (ANIK) has outperformed BioAge Labs (BIOA) over the past year, gaining 114.9% versus a gain of 11.8%. BioAge Labs is the larger company by market cap ($277.2 million vs $254.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIK | BIOA |
|---|---|---|
| Share price | $19.03 | $6.04 |
| Market cap | $254.68M | $277.22M |
| 1-day change | -2.56% | -3.51% |
| YTD return | +103.23% | -52.68% |
| 1-year return | +114.85% | +11.79% |
| 5-year return | -53.12% | — |
| Forward P/E | 20.03 | — |
| EPS (TTM) | $-0.23 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.88 | $25.96 |
| 52-week low | $8.67 | $5.04 |
| Distance from 52-week high | -16.83% | -76.73% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +20.86% | +489.90% |
| Average volume | 98.57K | 913.77K |
| Shares outstanding | 13.38M | 45.90M |
| Employees | 235 | 60 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIK has outperformed BIOA by 103.1 percentage points over the past year.
About Anika Therapeutics
ANIK stock →Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.
Health Care · Medical/Dental Instruments · 235 employees
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
ANIK vs BIOA FAQ
Which is bigger, Anika Therapeutics or BioAge Labs?
BioAge Labs (BIOA) is larger, with a market capitalization of $277.22M compared with $254.68M for Anika Therapeutics (ANIK).
Which stock has performed better over the past year, ANIK or BIOA?
ANIK returned +114.85% over the past 12 months, compared with +11.79% for BIOA (price return, excluding dividends). Past performance does not predict future results.
Are Anika Therapeutics and BioAge Labs in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Anika Therapeutics and Biotechnology: Pharmaceutical Preparations for BioAge Labs.